Background Lipopolysaccharide (LPS), an endotoxin found on the outer cell wall of Gram-negative bacteria, increases inflammatory response signaling and may play a role in the pathogenesis of several adverse outcomes, including inflammatory bowel diseases, cardiovascular disease, and cancer. While LPS is hypothesized to be associated with colorectal carcinogenesis, there are relatively few human studies which have examined this association. Methods We examined the association between colorectal cancer (CRC) and plasma lipopolysaccharide-binding protein (LBP), a marker of LPS, in 1,638 participants (819 CRC cases and 819 controls) matched on multiple factors, including age, sex, and race/ethnicity, from the Multiethnic Cohort study. Conditional logistic regression models were used to estimate the multivariable-adjusted odds ratios (OR) and 95% confidence intervals (95% CI). Results Compared to individuals whose LBP concentrations were in the lowest quartile, the ORs associated with second, third, and fourth quartiles were 1.23 (95% CI 0.91-1.67), 1.36 (95% CI 1.01-1.83), and 1.01 (95% CI 0.73-1.39), respectively, (p trend = 0.66). No differences were observed by BMI, fiber intake, saturated fat intake, cancer site, or cancer stage. Conclusions This study did not find an overall statistically significant association between LBP (as a marker of LPS exposure) and CRC. Further prospective studies with multiple LBP measurements are needed to validate current findings.
Introduction
Colorectal cancer (CRC) is the fourth most common incident cancer in the United States, with an estimated 135,430 new cases expected to occur in 2017 [1] . Recent research has pointed to a possible key role of gut microbial communities (GMC) in understanding the link between obesity, chronic inflammation, and the development of CRC [2] . Cani et al. identified lipopolysaccharide (LPS), a cell wall component of Gram-negative bacteria, as an underlying factor of obesity-driven low-grade inflammation [3] . High-fat, highcalorie diets, or high-carbohydrate diets have been shown to increase serum LPS concentrations [4, 5] while increasing age and obesity have also been shown to be positively associated with LBP [6, 7] .
LPS increases inflammatory response signaling, alters gut barrier function [8] , and may play a role in the pathogenesis of several adverse outcomes, including diabetes [9, 10] , inflammatory bowel disease [11] , cardiovascular disease [12, 13] , and cancer [14, 15] . LPS and lipopolysaccharidebinding protein (LBP), a marker of LPS exposure, have been shown to be associated with reduced apoptosis [16, 17] and increased proliferation in metastatic tumor cells [18, 19] in both in vitro and in vivo experimental studies. Several studies have shown that LBP polymorphisms (LBP SNPs 1 3 rs2232613 and rs2232571) were associated with increased plasma LBP concentrations [20] [21] [22] , suggesting that the increased risk of CRC associated with certain polymorphisms may be caused by increased levels of circulating LBP.
In vitro studies have shown that LPS promotes cancer-cell survival and proliferation, angiogenesis, vascular permeability, and tumor cell adhesion [16, 19, 23, 24] ; however, to our knowledge, no epidemiologic studies have prospectively examined the association between LBP and CRC risk. Thus, the goal of this study was to examine whether pre-diagnostic plasma LBP concentrations were associated with CRC incidence in a case-control study nested within a prospective cohort study.
Methods

Study population and overview
The Multiethnic Cohort (MEC) is a longitudinal study designed to investigate the association of dietary, lifestyle, and genetic factors with the incidence of cancer and other chronic diseases [25] . The MEC includes 215,251 men and women primarily from five different racial-ethnic groups [African Americans, Japanese Americans, Latinos, Native Hawaiians, and whites in Hawaii and California (mostly in Los Angeles county)] aged 45-75 years at recruitment. The cohort was assembled in 1993-1996 by mailing a selfadministered, 26-page questionnaire to individuals identified primarily through the driver's license files from Hawaii and California. The baseline questionnaire obtained information on demographics, medical and reproductive histories, cigarette smoking, medication use, family history of various cancers, physical activity, and a quantitative food frequency questionnaire (FFQ). In Year 5 of the follow-up (1999-2001), a short questionnaire updated information on medical conditions and history, including screening tests for cancer. A 10-year update of the dietary and other exposure data was completed between 2003 and 2008 by re-administration of the full baseline questionnaire. The Institutional Review Boards at the University of Hawaii and the University of Southern California approved the study protocol.
Ascertainment of case status, site and stage
Identification of incident cancer cases was achieved by regular linkage with the Hawaii Tumor Registry, the Los Angeles County Cancer Surveillance Program, and the State of California Cancer Registry, all of which are members of the NCI Surveillance, Epidemiology, and End Results (SEER) program [26] . Deaths in the cohort were identified by linkage to the state death-certificate files in CA and HI, and to the National Death Index for deaths occurring in other states. Colon cancer cases included those with ICD-O-3 codes of C18.0-C18.9 and rectal cancer cases were those with ICD-O-3 codes of C19.9 and C20.9. Histologies > 9,000 (large intestinal neoplasms with hematopoietic lineages) were excluded. SEER summary stage was used, which defines localized cancer as cancer that is limited to the organ of origin, regional as cancer spread beyond the original site to nearby lymph nodes or organs and tissues, and distant as cancer that has spread to distant organs or distant lymph nodes.
Individuals with a history of CRC prior to their phlebotomy date, based on the baseline questionnaire and/or linkage to the SEER registries, were excluded. A total of 846 colorectal cases whose diagnoses occurred after blood collection and before the censor date (10/2013) were initially identified for LBP assessment. Two cases who were ultimately discovered to have in situ tumors, as well as 25 cases with unspecified tumor stage, were excluded (as we could not ascertain tumor stage) leaving 819 cases with invasive cancers of the colon and rectum.
For this analysis, a nested case-control design was used, matching controls to CRC cases on a 1-1 ratio. For each case, a control pool was created consisting of cohort members who had donated specimens and who were alive and have never been diagnosed with CRC at the age of the case's diagnosis. Controls were matched to cases on birth year, location (Hawaii or Los Angeles), sex, ethnicity, age at phlebotomy (within ± 1 year), date of specimen collection (± 1 month), time of blood collection (± 2 h), and time since last meal (± 2 h).
LBP exposure assessment
Between 2001 and 2006, biospecimens, which included fasting blood samples, as well as a short questionnaire on current medication and dietary supplement use were collected from surviving members of the MEC who reside in the catchment areas of the research centers in Hawaii and Los Angeles. This biorepository includes approximately 70,000 subjects who are broadly representative of all cohort members [27] . The majority of these participants (72%) also provided responses to the follow-up questionnaires as described above.
For this study, the circulating concentration of LBP was measured in heparinized plasma using a commercial ELISA kit (Cell Sciences Inc) designed for either heparinized plasma or serum samples. Samples were diluted 1:1,000 and the assay was conducted according to the kit protocol with a standard curve of 1.5-100 ng/mL. Ten percent of samples were blinded quality control duplicates, and laboratory personnel were blinded to the case-control status of the participants. Samples for matched cases and controls were positioned in random order next to each other in the same batch in order to reduce bias due to laboratory variation. Based on the QC duplicate samples, the intra-and interbatch coefficient of variation percent (CV%) was 4.3 and 11.3, respectively.
Statistical analysis
LBP was categorized into quartiles with the cutoff for each quartile determined using control values. Conditional logistic regression with matched sets as strata was used to compute odds ratios (ORs) and 95% confidence intervals (CIs) for the relationship between LBP and CRC in the minimally adjusted model. Additional adjustment for covariates not matched on was performed in the multivariable model.
Covariates included in multivariable analyses were selected a priori (see Table 1 ), and included factors associated with LBP, LPS, and/or CRC. The multivariable model included the following covariates evaluated at baseline: education (less than high school, high school graduation, some college, college graduate or higher), history of intestinal polyps (yes or no), diabetes (yes or no), history of CRC among first-degree relatives (yes or no), BMI (kg/m 2 , categorized according to federal guidelines [28] : underweight (< 18.5), normal weight (18.5-24.9), overweight (25-29.9), and obese (≥ 30), with normal weight serving as the reference group), aspirin-use status (never, yes currently, yes formerly), alcohol consumption (g/day, categorized based on one standard drink equaling 14 g alcohol and the Department of Agriculture and Department of Health & Human Services recommendation of no more than 1 drink/day for women and 2 drinks/day for men [29] , women: non-drinker [0 g/day], 0.1 to <14 g/day, and ≥ 14 g/day; men: non-drinker [0 g/day], 0.1 to <28 g/day, and ≥ 28 g/day), relative density of dietary fiber (g/1,000 kcal/day) and saturated fat (% of energy, calculated as 9*g saturated fat/kcal intake), and physical activity (METs/day). Dietary fiber intake, saturated fat intake, and physical activity were categorized into tertiles based on the distribution among controls.
Additionally, previous colonoscopy or sigmoidoscopy (yes or no) reported at the 5-year follow-up questionnaire, as well as non-aspirin NSAID use (yes or no), hormone replacement therapy use (yes or no/refused/don't know), and smoking status (never, current, former) at the time of blood draw were included in the multivariable model. We created a "missing" category for covariates with missing data in order to reduce the number of participants who would be dropped from the analysis.
Stratified analyses were performed to examine the association between LBP and CRC risk by BMI, dietary fiber intake, and saturated fat intake at baseline, dichotomized at the median values of controls. p values for interaction were calculated by including a single cross-product term between LBP concentration, modeled as an ordinal variable, and the binary variable (BMI, saturated fat, or dietary fiber) in a single model, adjusted for the covariates listed above.
We also evaluated heterogeneity of the LBP-CRC association by cancer site (colon vs. rectum), and cancer stage (local vs. regional/distal) at time of diagnosis. In the case of synchronous colorectal cancers (n = 18), the tumor with the higher stage was used. Four individuals were excluded from the analysis of LBP-CRC by tumor site as they had diagnosed tumors in both the colon and the rectum that were at the same stage. Conditional logistic regression restricting cases to specific sites/stages was used to determine point estimates and corresponding 95% CI while unconditional logistic regression limited to cases (where regional or colon cancers were coded as cases and local or rectal cases were coded as controls) was used to determine statistical significance (p for difference) of subsite-and stage-specific differences. These regression models were adjusted for all covariates listed above as well as the matching variables sex, age, study site, and time since last meal.
A sensitivity analysis, which excluded all cases diagnosed within 1 year of follow-up, was performed to address the possibility that preclinical CRC may influence circulating LBP concentrations. Further sensitivity analyses were performed by replacing baseline covariates with responses from follow-up questionnaire to examine any potential bias that may have occurred from the temporal discordance in blood and questionnaire collection-as the blood was drawn several years after the baseline questionnaire was administered. Additionally, we also reanalyzed the association between LBP and CRC including only those individuals with complete data to explore whether missing covariate data may have influenced results. A final sensitivity analysis dropping individuals with implausible dietary values (calories: < 700 or > 4,200 kcal/day (n = 126), alcohol: > 100 g/day (n = 61) and weight measures (BMI: < 15 or > 50 (n = 3), total dropped = 144) was performed to examine bias introduced from individuals with extreme measurements.
All reported p values are two-sided, and a p value < 0.05 was considered statistically significant. All analyses were carried out using STATA 14 (StataCorp, College Station, TX). Table 1 presents the distributions and means of the study covariates by matched case-control status (819 controls and 819 cases). Compared to controls, a history of diabetes was more prevalent among cases, while controls were more likely to be current smokers. Japanese represented the largest ethnicity among cases (n = 305), accounting for more than a third of total cases. Cases were more likely to be Table 2 . Overall LBP concentrations were not statistically significantly associated with CRC risk in either the minimally adjusted or the multivariable-adjusted models.
Results
In the fully adjusted model, the OR among those in the third quartile was statistically significantly higher than that in the lowest quartile (OR 1.36; 95% CI 1.01-1.83). However, there was no observed increased risk among those in the highest LBP quartile (OR 1.01; 95% CI 0.73-1.39) and the test for trend was not statistically significant (p trend = 0.66). Table 3 presents analyses of the findings related to LBP concentrations, stratified by BMI, dietary fiber intake, and saturated fat intake, respectively. Among individuals in the high-BMI (> 26.12 kg/m 2 , median at blood draw) group, there was a statistically significantly increased risk for those in the third quartile versus first quartile (Q3: OR 1.35; 95% CI 1.01-1.81). Associations were slightly attenuated, albeit similar, in the low-BMI (≤ 26.12 kg/m 2 ) group, and there was no evidence of heterogeneity between the groups (p interaction = 0.24). The association of higher LBP concentration and CRC risk was more apparent among individuals in the lower fiber category (vs. higher fiber), with a non-statistically significant trend observed across quartiles (p trend = 0.10); however, there was no apparent heterogeneity between fiber groups (p interaction = 0.12). In both the high-and low-saturated fat groups, the positive association between LBP and CRP was most pronounced in the third tertile, but there were no apparent trends in CRC risk by LBP quartile in either group and no interaction between saturated fat intake and LBP on CRC risk (p interaction = 0.36). Table 4 presents analyses of LBP concentration and CRC by anatomic subsite, and cancer stage at diagnosis. While ORs across quartiles varied by cancer site (colon vs. rectum), these differences were not statistically significant (all p difference = 0.45). The association between LBP concentration and CRC risk was similar for local and regional/distant disease, with no evidence of heterogeneity (all p difference = 0.52).
In a sensitivity analyses, the associations between LBP concentration and CRC risk remained virtually unchanged after excluding cases diagnosed within 1 year of follow-up, after excluding individuals with extreme dietary and weight measurements, and after excluding those with missing covariate data (data not shown). 
Discussion
Results from this study do not provide clear evidence of an association between plasma LBP concentrations and CRC risk. Additionally, there was no evidence of differential effects by BMI, dietary fiber intake, saturated fat intake, cancer site, or cancer stage. However, the stratified results in Table 3 led to small numbers in some subgroups and limited power to detect significant main effects or interactions. LPS is hypothesized to be associated with colorectal carcinogenesis, but relatively few human studies have examined this association, and no studies have examined the association between circulating LBP concentrations and CRC specifically. A recent cross-sectional study of individuals undergoing colonoscopy found that those with higher plasma LPS concentrations were more likely to have adenomas compared to those with low LPS concentrations [odds ratio (OR) 1.4, 95% CI 1.0-2.1], and this excess risk was independent of cytokine levels (TNF-α, IL-4, IL-6, IL-8, IL-10, IL-12, IL-17, and IFN-γ) [14] . Additionally, a recent prospective study showed that polymorphisms in the LBP gene (GA and GG genotypes of LBP rs2232596) correlated with increased CRC risk (OR 1.51, 95% confidence interval (CI) 1.15-1.99, p = 0.003; OR 2.49, 95% CI 1.16-5.38, p = 0.016, respectively) [30] . Differences in results may be due to study design and use of adenomas, rather than CRC, in the first study, and the use of LBP genes (not plasma LBP) in the second study [14] .
Use of an endogenously produced biomarker such as LBP, which reflects the host's response to microbial products, can be influenced by various inflammatory factors; LPS transfer into the bloodstream may be caused by factors such as tissue damage, infection, or other medical conditions which may induce systemic inflammation As a result, in the cross-sectional study of Kang et al. [14] , the higher concentrations observed in the adenoma cases may be a byproduct, Table 3 Odds ratios (OR) of colorectal cancer associated with LBP concentrations, stratified by potential effect modifiers Adjusted for education, BMI (kg/m 2 ), physical activity, smoking status at time of blood draw, history of intestinal polyps, previous colonoscopy or sigmoidoscopy, diabetes, history of CRC among 1st degree relatives, NSAID use, aspirin use, alcohol consumption, dietary fiber intake, saturated fat intake, and hormone replacement therapy use among women a Matched on: age, location (Hawaii or California), sex, ethnicity, age at phlebotomy, date of specimen collection, time of blood collection, and time since last meal not a cause, of the adenoma. The MEC participants in the current study were healthy at the time of blood draw, which, in turn, may have reduced the likelihood that associations would be confounded by illness or medical conditions, such as colorectal adenomas. Thus, differences in study results may be due to timing at which LBP concentrations were ascertained relative to the neoplasm diagnosis. While LBP binds to LPS, the protein also recognizes the lipoteichoic acid of Gram-positive bacteria, as well as structurally similar spirochetal glycolipids [31, 32] . Nonetheless, it should be noted that the LBP assay is more reliable than the one used for LPS, given the large amount of interference in the limulus amebocyte lysate (LAL) assay [33] ; moreover, in addition to difficulties with the assay, the need to collect samples under LPS-free conditions and high variability of LPS throughout the day may make LBP is a more stable marker [34, 35] . As such, inconsistencies between current results and previous studies may have been due to inherent differences between LPS and LBP, as well as the assays used to measure them.
Human studies have shown that LPS concentrations are higher in participants who consume a high-fat diet [6] , and that postprandial LPS concentrations rise significantly after a high-fat meal [4, 5, 36, 37] . While our study obtained fasting blood samples from healthy individuals to minimize the influence of short-term factors that may affect LBP concentrations, such as diet or illness, residual confounding may have persisted, as, at least in sepsis patients, LBP remains elevated for 12-24 h following exposure-thus a high-calorie, high-fat meal the night before the blood draw may have led to a higher LBP concentration.
Additionally, it is important to note that the range in LBP concentrations in the current population was outside of normal healthy population limits. Based on previous literature, LBP concentrations in plasma range from 1 to 24 µg/mL among healthy individuals [38, 39] . However, in the current population, LBP ranged from 1 to 107.5 µg/mL (cases range 2-107.5 µg/mL; control range 4-100.4 µg/mL). LBP in the current population was normally distributed in both cases and controls (data not shown). It is possible that the wide ranges may have been a consequence of processing times or long storage periods (samples were stored at − 180 °C for roughly 10 years), although there are currently no studies examining how LBP measurements change in stored samples over time. The possibility that a delay in processing times led to artificially higher LBP concentrations in some of the samples may help to explain why a positive trend was seen between LBP concentration and CRC risk in the second and third quartile, but not the fourth (highest, which would have been erroneously high). However, this scenario is unlikely given that all blood samples were drawn and processed within 4 h of collection by centrifugation, in accordance with the study protocol. As such, additional research is needed to explain how LBP concentrations may change in stored frozen samples over time.
Strengths of the study include its prospective design which allowed for LBP concentration levels prior to diagnosis of CRC to be measured, thus reducing bias resulting from reverse causality. Additionally, excluding cancer cases identified during the first year of follow-up did not impact results, a finding that supports the likelihood that reverse causality did not influence point estimates. Lastly, our findings for LBP concentration and CRC by stage suggest that the associations were not stronger for those with more advanced stage, as would be expected if disease stage affected LBP.
Study limitations include the use of single measure of LBP. LBP is an acute phase reactant and is influenced by a range of factors; one measure may not capture average longterm LBP concentrations within an individual. A previous study of the reliability of LBP showed that the intraclass correlation coefficient over a 3-month period ranged from 0.49 to 0.6, with shorter follow-up times corresponding to a higher ICC [40] . Therefore, multiple measures would be optimal for precise LBP measurement, especially for longer periods of exposure.
In summary, we did not find an association between LBP and CRC, nor did we find an association by BMI, saturated fat intake, dietary fat intake, cancer site, or cancer state. However, given that this was the first study to examine this association, future prospective studies are needed to validate findings and development of complementary biomarkers of this process may be warranted.
